Defunct Company
Total Trials
10
As Lead Sponsor
8
As Collaborator
2
Total Enrollment
374
NCT00692354
Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2004
Completion: Mar 31, 2008
NCT00689000
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
Phase: Phase 1/2
Start: May 31, 2006
Completion: Dec 31, 2007
NCT00737555
A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
Start: Aug 31, 2006
NCT00522938
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Start: Dec 31, 2007
Completion: Apr 30, 2008
NCT00697879
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
Start: Feb 29, 2008
Completion: Nov 30, 2011
NCT00820508
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
Start: Dec 31, 2008
Completion: Jul 31, 2011
NCT00780598
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
Phase: Phase 2
Start: Oct 31, 2009
Completion: Mar 31, 2011
NCT01180426
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
Start: Jun 30, 2010
Completion: Jun 30, 2013
NCT01638442
Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects
Role: Collaborator
Start: Jun 30, 2012
Completion: Sep 30, 2012
NCT02759601
Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)
Start: Jan 31, 2013
Completion: Dec 31, 2018